High blood pressure is the most common chronic condition in American adults and one of the best-served by existing medicine. There are five well-established drug classes, most of them inexpensive generics, and for the large majority of patients some combination of them works. The problem has always been the minority for whom it does not.

In May the FDA approved baxdrostat, sold as Baxfendy, as the first aldosterone synthase inhibitor, for use alongside other antihypertensives in adults whose blood pressure is not adequately controlled. In the pivotal trial it lowered seated systolic pressure by about 9.8 mmHg more than placebo at the 2 mg dose, in people already taking two or more other medications. For a population defined by having failed the existing options, that is a meaningful number.

From the Lab to the Ledger

Aldosterone is a hormone made in the adrenal gland that tells the kidney to hold on to sodium and water. More sodium and water in circulation means higher pressure. In a subset of people with hard-to-treat hypertension, aldosterone levels are inappropriately high, and no amount of adding conventional drugs addresses the thing actually driving the pressure.

Medicine has had a partial answer for decades. Spironolactone and related drugs block the receptor aldosterone acts on, which is why they are standard fourth-line therapy for resistant hypertension. Their limitation is selectivity: the same receptor family governs sex hormone signalling, so spironolactone causes breast tenderness in men and menstrual irregularity in women often enough to limit its use.

Baxdrostat takes a different route. Rather than blocking the receptor, it inhibits aldosterone synthase, the enzyme encoded by CYP11B2 that produces the hormone in the first place. The engineering challenge was selectivity of a different kind: the enzyme that makes cortisol is a close relative, and inhibiting it would cause adrenal insufficiency. Across a wide dose range, baxdrostat lowered aldosterone without measurably affecting cortisol.

The pivotal BaxHTN trial randomized 796 patients to 2 mg, 1 mg or placebo on top of their existing treatment, over a 12-week blinded period. Seated systolic pressure fell 15.7 mmHg on 2 mg and 14.5 mmHg on 1 mg, against 5.8 mmHg on placebo. Results held across both the uncontrolled and the treatment-resistant subgroups, and a second Phase 3 trial using 24-hour ambulatory monitoring also met its primary endpoint.

Bio-Pipeline Ledger

Baxdrostat: approved in the US as a first-in-class aldosterone synthase inhibitor, 2 mg once daily, 1 mg for patients at higher risk of electrolyte problems. Commercially available, as add-on therapy rather than a first-line drug.

Spironolactone and other mineralocorticoid receptor antagonists: long-established, cheap and effective fourth-line therapy, limited by hormonal side effects from receptor cross-reactivity.

Standard first-line classes: ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, thiazide diuretics and beta blockers remain well validated, inexpensive and sufficient for most patients. Nothing here displaces them.

Renal denervation: a catheter procedure for resistant hypertension, approved with an evidence base that remains debated. Available in selected centres.

Other aldosterone-pathway and siRNA approaches to hypertension: several candidates in trials, including agents designed for less frequent dosing. Early to mid clinical stage, not validated for broad use.

The Clinical Reality Check

The population this helps is specific: adults already on two or more drugs, one of them usually a diuretic, whose pressure is still too high. That is a real and sizeable group, and until now their options narrowed quickly. It is not a drug for someone newly diagnosed, and it is not a substitute for the cheap generics that handle most hypertension perfectly well.

The safety profile requires attention rather than alarm. Hyperkalaemia, too much potassium in the blood, occurred in about 6.6 percent of patients on 1 mg and 10.2 percent on 2 mg in pooled trials, against low rates on placebo. The label instructs clinicians to check potassium before starting and periodically afterwards, more often in patients over 65 and in those with diabetes or chronic kidney disease, and to stop the drug permanently if clinically significant hyperkalaemia recurs. Low sodium is monitored the same way. These are manageable with blood tests, and they are why this is a monitored drug rather than a simple add-on.

What has not been shown yet is the thing that matters most. The trials measured blood pressure, which is a reliable surrogate but still a surrogate. Nobody has yet demonstrated that baxdrostat reduces strokes, heart attacks or deaths, and the drugs it joins have that evidence behind them. Outcome data will take years, and the approval rests on the long-established relationship between lowering pressure and lowering risk rather than on direct proof for this agent.

For anyone whose blood pressure has stayed high despite several medications, this is a reasonable thing to raise at the next appointment, specifically as a question about whether aldosterone might be the driver. That is a question a physician can investigate with ordinary blood tests, and it is more useful than asking about the drug by name.